Related Experiment Video
Updated: Jul 2, 2025
Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications
Published on: October 11, 2024
Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer
Yujin Guo1,2, Beibei Chen2, Jinxiu Guo2
1Institute of Clinical Pharmacy, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Context:
Podophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.
Objective:
This study synthesizes PPT derivatives to assess their anticancer activities.
Materials And Methods:
Compounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay. The effects of compound E5 on A549 cell growth were evaluated through molecular docking, in vitro assays (flow cytometry, wound healing, Transwell, colony formation, Western blot), and in vivo tests in female BALB/c nude mice treated with E5 (2 and 4 mg/kg). E5 (4 mg/kg) significantly reduced xenograft tumor growth compared to the DMSO control group.
Results:
Among the 16 PPT derivatives tested for cytotoxicity, E5 exhibited potent effects against A549 cells (IC50: 0.35 ± 0.13 µM) and exceeded the reference drugs PPT and etoposide to inhibit the growth of xenograft tumours. E5-induced cell cycle arrest in the S and G2/M phases accelerated tubulin depolymerization and triggered apoptosis and mitochondrial depolarization while regulating the expression of apoptosis-related proteins and effectively inhibited cell migration and invasion, suggesting a potential to limit metastasis. Molecular docking showed binding of E5 to tubulin at the colchicine site and to Akt, with a consequent down-regulation of PI3K/Akt pathway proteins.
Discussion And Conclusions:
This research lays the groundwork for advancing cancer treatment through developing and using PPT derivatives. The encouraging results associated with E5 call for extended research and clinical validation, leading to novel and more effective cancer therapies.
Insights
New podophyllotoxin (PPT) derivatives show promise in cancer therapy. Compound E5 effectively inhibits cancer cell growth and tumor development, warranting further clinical research for novel cancer treatments.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Podophyllotoxin (PPT) derivatives are utilized in cancer therapy but require optimization for efficacy and reduced toxicity.
- Development of novel PPT derivatives is crucial for advancing cancer treatment strategies.
Purpose of the Study:
- To synthesize and evaluate the anticancer activities of novel PPT derivatives.
- To investigate the detailed mechanisms of action for the most potent derivative, E5.
Main Methods:
- Synthesis of 16 PPT derivatives (E1-E16).
- Antiproliferative activity assessed via CCK-8 assay against human cancer and normal cell lines.
- In-depth analysis of E5 using molecular docking, in vitro assays (flow cytometry, wound healing, Transwell, colony formation, Western blot), and in vivo xenograft models.
Main Results:
- Compound E5 demonstrated potent cytotoxicity against A549 cells (IC50: 0.35 ± 0.13 µM), outperforming reference drugs.
- E5 induced S and G2/M phase cell cycle arrest, tubulin depolymerization, apoptosis, and mitochondrial depolarization.
- E5 significantly inhibited tumor growth in vivo and suppressed cancer cell migration and invasion, with molecular docking revealing interactions with tubulin and the PI3K/Akt pathway.
Conclusions:
- The synthesized PPT derivative E5 exhibits significant anticancer properties, including tumor growth inhibition and anti-metastatic potential.
- E5's mechanism involves tubulin interaction and PI3K/Akt pathway modulation.
- These findings support further investigation and clinical validation of E5 as a potential novel cancer therapeutic.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...